Introduction: The emergence of multidrug-resistant gram-negative bacteria has led to the
increasing use of polymyxins. Nephrotoxicity and, to a lesser degree, neurotoxicity occur …

Introduction The epidemic dimensions of emergence of multi-drug resistant Gram-negative
bacterial infections have led to the revival of old antibiotics, including polymyxins. Methods …

Nephrotoxicity was assessed in 173 critically ill patients receiving intravenous colistin or
polymyxin B; it occurred in 60.4% and 41.8%, respectively. Further investigation is …

Polymyxin B is used as an antibiotic of last resort for patients with multidrug-resistant Gram-
negative bacterial infections; however, it carries a significant risk of nephrotoxicity. Herein …

Objectives Polymyxin B is an active agent against many MDR Gram-negative bacteria, but
nephrotoxicity is a major hindrance to its widespread use. To guide its optimal use, we …

Polymyxins are reserved for salvage therapy of infections caused by carbapenem-resistant
Klebsiella pneumoniae (CRKP). Though synergy has been demonstrated for the …

Aims Data regarding clinical pharmacokinetic/toxicodynamic (PK/TD) of polymyxin B is short
of direct quantitative data. This study aims to investigate the risk factors of polymyxin B …

Introduction The correlation between total and free polymyxin B (PMB including PMB1 and
PMB2) exposure in vivo and acute kidney injury (AKI) remains obscure. This study explores …

Objectives This study aimed to assess the current incidence and risk factors for polymyxin B-
associated acute kidney injury (AKI) in Chinese hospitals for a more effective clinical use for …

Nephrotoxicity is a known adverse effect of polymyxin B (PMB). Animal data suggest that
once-daily dosing may reduce the rate and delay the onset of acute kidney injury (AKI). In a …